![Murty Bosukonda](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Murty Bosukonda active positions
Companies | Position | Start | End |
---|---|---|---|
Thrasos, Inc.
![]() Thrasos, Inc. Pharmaceuticals: MajorHealth Technology Thrasos, Inc. discovers and develops drugs. The company develops protein mimetic compounds for Kidney and Heart disease. Thrasos is headquartered in Hopkinton, MA | Director/Board Member | - | - |
Career history of Murty Bosukonda
Former positions of Murty Bosukonda
Companies | Position | Start | End |
---|---|---|---|
Thrasos Therapeutics, Inc.
![]() Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Founder | 31/12/2002 | - |
Statistics
International
United States | 2 |
Canada | 2 |
Operational
Director/Board Member | 1 |
Founder | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Thrasos, Inc.
![]() Thrasos, Inc. Pharmaceuticals: MajorHealth Technology Thrasos, Inc. discovers and develops drugs. The company develops protein mimetic compounds for Kidney and Heart disease. Thrasos is headquartered in Hopkinton, MA | Health Technology |
Thrasos Therapeutics, Inc.
![]() Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Health Technology |
- Stock Market
- Insiders
- Murty Bosukonda
- Experience